Aastrom Biosciences Inc (NASDAQ:ASTM)
CAPS Rating:
The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.
RSS Headlines
Fool UK
Recs
Their TRC's are non-invasive, personal blood stem cells, being proven a success in clinics and create no side affects. Also non-controversal and morally acceptable.
wyn harter